SCHEDULE 13G/A – Description
Allogene Therapeutics, Inc.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics…
Allogene Therapeutics Announces Participation in March Investor Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™…
- 1
- 2
- 3
- 4
- …
- 16
- Go to the next page